Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 504

1.

Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.

Chien J, Liu J, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Yang HI, Chen CJ.

J Gastroenterol Hepatol. 2016 Dec;31(12):1971-1977. doi: 10.1111/jgh.13422.

PMID:
27118149
2.

Natural history of chronic hepatitis B REVEALed.

Chen CJ, Yang HI.

J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. Review.

PMID:
21323729
3.

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ; R.E.V.E.A.L.-HBV Study Group.

Hepatology. 2013 Aug;58(2):546-54. doi: 10.1002/hep.26385.

PMID:
23504622
4.

A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P.

Gastroenterology. 2014 May;146(5):1249-55.e1. doi: 10.1053/j.gastro.2014.01.045. Epub 2014 Jan 23.

5.

Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.

Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL–HBV) Study Group.

Gastroenterology. 2011 Oct;141(4):1240-8, 1248.e1-2. doi: 10.1053/j.gastro.2011.06.036. Epub 2011 Jun 22.

PMID:
21703214
6.

Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.

Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

Liver Int. 2018 Jan;38(1):68-75. doi: 10.1111/liv.13489. Epub 2017 Jul 3.

PMID:
28581248
7.

Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.

Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH.

Hepatology. 2012 Jan;55(1):68-76. doi: 10.1002/hep.24615.

PMID:
21858846
8.

What can we learn from hepatitis B virus clinical cohorts?

Lin CL, Tseng TC, Kao JH.

Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Review.

PMID:
25529093
9.

Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.

Fung J, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF.

Hepatology. 2018 Aug;68(2):462-472. doi: 10.1002/hep.29874. Epub 2018 Jun 6.

PMID:
29534307
10.

Perspectives and control of hepatitis B virus infection in Taiwan.

Lin CL, Kao JH.

J Formos Med Assoc. 2015 Oct;114(10):901-9. doi: 10.1016/j.jfma.2015.06.003. Epub 2015 Jul 13. Review.

11.

Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.

Kim EJ, Yeon JE, Kwon OS, Lee HN, Shin SK, Kang SH, Byun KS, Kim JH, Kwon SY, Suh SJ, Yim HJ, Kim YS, Kim JH.

Dig Dis Sci. 2017 Mar;62(3):808-816. doi: 10.1007/s10620-016-4431-8. Epub 2016 Dec 29.

PMID:
28035553
12.

Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.

Poh Z, Goh BB, Chang PE, Tan CK.

Eur J Gastroenterol Hepatol. 2015 Jun;27(6):638-43. doi: 10.1097/MEG.0000000000000341.

13.

Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.

Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS.

World J Gastroenterol. 2013 Oct 28;19(40):6834-41. doi: 10.3748/wjg.v19.i40.6834.

14.

Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.

Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ.

Ann Hepatol. 2014 Jul-Aug;13(4):386-93.

15.

Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.

Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ.

PLoS One. 2013 Apr 17;8(4):e61448. doi: 10.1371/journal.pone.0061448. Print 2013.

16.

Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.

Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ.

J Natl Cancer Inst. 2009 Jul 15;101(14):1019-27. doi: 10.1093/jnci/djp146. Epub 2009 Jun 17.

PMID:
19535774
17.

A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation.

Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y.

Medicine (Baltimore). 2016 Sep;95(36):e4832. doi: 10.1097/MD.0000000000004832.

18.

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, Farinati F, Naccarato R.

Cancer. 1999 May 15;85(10):2132-7.

PMID:
10326690
19.

Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.

Caviglia GP, Abate ML, Gaia S, Petrini E, Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, Rizzetto M, Smedile A.

Panminerva Med. 2017 Dec;59(4):283-289. doi: 10.23736/S0031-0808.17.03353-5. Epub 2017 Jun 23.

PMID:
28650134
20.

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.

Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group.

Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.

PMID:
21270118

Supplemental Content

Support Center